Lydia Reinhardt

Dresden, SN, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)-an AIO/ABCSG trial.

Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)-an AIO/ABCSG trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 20, 2026

Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients.

Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 03, 2025

Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma.

Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 03, 2025

Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study.

Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study.

Journal: ESMO open

Published: April 26, 2024

BMP, MEK, and WNT inhibition with NGN2 expression for rapid generation of hiPSC-derived neurons amenable to regional patterning.

BMP, MEK, and WNT inhibition with NGN2 expression for rapid generation of hiPSC-derived neurons amenable to regional patterning.

Journal: Stem cell reports

Published: January 18, 2024

Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.

Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 10, 2024

Axonal Lysosomal Assays for Characterizing the Effects of LRRK2 G2019S.

Axonal Lysosomal Assays for Characterizing the Effects of LRRK2 G2019S.

Journal: Biology

Published: November 10, 2023

Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.

Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 17, 2023

General practitioners' perspectives on statutory skin cancer screening-A questionnaire-based cross-sectional survey in Germany.

General practitioners' perspectives on statutory skin cancer screening-A questionnaire-based cross-sectional survey in Germany.

Journal: PloS one

Published: June 08, 2023

Quality, Understandability and Reliability of YouTube Videos on Skin Cancer Screening.

Quality, Understandability and Reliability of YouTube Videos on Skin Cancer Screening.

Journal: Journal of cancer education : the official journal of the American Association for Cancer Education

Published: May 31, 2023

Establishment of a high-content imaging assay for tau aggregation in hiPSC-derived neurons differentiated from two protocols to routinely evaluate compounds and genetic perturbations.

Establishment of a high-content imaging assay for tau aggregation in hiPSC-derived neurons differentiated from two protocols to routinely evaluate compounds and genetic perturbations.

Journal: SLAS discovery : advancing life sciences R & D

Published: May 22, 2023

Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study.

Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 07, 2023

Showing 1-12 of 45

Last Updated: 09/26/2026